Company Overview and News
We believe that Zebra Technologies Corporation (ZBRA - Free Report) is a solid choice for investors seeking exposure in the machinery space. The stock, with $9.1 billion of market capitalization, has been upgraded to a Zacks Rank #1 (Strong Buy) on Aug 22. The company delivered better-than-expected results in the four trailing quarters, with an average positive earnings surprise of 13.28%. Why the Upgrade? We are providing a snapshot of how Zebra Technologies fared in second-quarter 2018.
XPLR TOL AIMC B ZBRA GTLS
Zebra Technologies Corporation (ZBRA - Free Report) recently introduced a vertical specialization program for providers of health care technology. Notably, the program will be available in North America, Latin America and parts of Asia-Pacific including Australia, New Zealand, South Korea and India.
XPLR AIMC TTEK ZBRA
Zebra Technologies Corporation (ZBRA - Free Report) recently marked its 10th year of business deal with Auto Parte Y Mas S.A.’s (“APYMSA”) distribution center through which the company provides technologies for improving the workforce and operational processes of the latter. Prior to this, on Aug 14, Zebra Technologies successfully completed the acquisition of Xplore Technologies Corporation.
XPLR HD ADES AIMC ALG ZBRA OXY
xplore20180813_8k.htm UNITED STATES
The tender offer by Zebra Technologies Corp (ZBRA) to acquire all of the outstanding shares of Xplore Technologies Corp (XPLR) is scheduled to expire at midnight ET on August 13, 2018, unless extended or terminated. The subsequent merger is expected to close on August 14, 2018. The details are as follows:
Good day and welcome to the Second Quarter 2018 Zebra Technologies' Earnings Conference Call. All participants will be in listen-only mode. After today's presentation, there will be an opportunity to ask questions. Please note this event is being recorded.
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
as of ET